Taiwan FDA registration 407f671aad979c092af1b6a6a20bfa9a
BD MAX fully automatic meristem detection system
TW: BD MAX 全自動分生檢測系統
Taiwan·Risk Class 2·BECTON, DICKINSON AND COMPANY·Registered Apr 20, 2021 – Apr 20, 2026ExpiredRegistration details
- Analysis ID
- 407f671aad979c092af1b6a6a20bfa9a
- Customs Code
- DHA05603439705
Company information
- Manufacturer
- BECTON, DICKINSON AND COMPANY
- Manufacturer Country
- United States
- Authorized Representative
- BECTON DICKINSON HOLDINGS PTE. LTD. TAIWAN BRANCH (SINGAPORE)
Product details
- Intended Use
- BD MAX systems, when used with appropriate extraction panels and reagents, can automatically extract and purify nucleic acids from a variety of sample types. BD MAX systems can also automatically amplify and detect nucleic acid sequences of interest.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.2570 Clinical Multi-standard Detection System Instrument
- Import Information
- Input;; QMS/QSD
Dates and status
- Registration Date
- Apr 20, 2021
- Expiry Date
- Apr 20, 2026
About this record
Access comprehensive regulatory information for BD MAX fully automatic meristem detection system in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 407f671aad979c092af1b6a6a20bfa9a and manufactured by BECTON, DICKINSON AND COMPANY. The authorized representative in Taiwan is BECTON DICKINSON HOLDINGS PTE. LTD. TAIWAN BRANCH (SINGAPORE).
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices